The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors

Climacteric

Volumn 11, Issue 6, 2008, Pages 489-497

  Skouby, S O ^a,b,d   Sidelmann, J J ^b   Nilas, L ^a   Gram, J ^b,c   Jespersen, J ^b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ESBJERG HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular risk markers; Conjugated estrogens; Hormone therapy; Insulin sensitivity; Medroxyprogesterone; Tibolone

Indexed keywords

C REACTIVE PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLASMINOGEN ACTIVATOR INHIBITOR; TIBOLONE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION;

BLOOD PRESSURE; BODY COMPOSITION; C-PEPTIDE; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ESTROGEN RECEPTOR MODULATORS; ESTROGENS, CONJUGATED (USP); FEMALE; FIBRINOLYSIS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; METABOLIC SYNDROME X; MIDDLE AGED; NORPREGNENES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 57349150247     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130802455150     Document Type: Article

References (43)

1. Sipila S. Body composition and muscle performance during menopause and hormone replacement therapy. J Endocrinol Invest 2003;26:893-901
2. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003;88:2404-11
3. Otsuki M, Kasayama S, Morita S, et al. Menopause, but not age, is an independent risk factor for fasting plasma glucose levels in nondiabetic women. Menopause 2007;14:404-7
4. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004;24:e13-18
5. Fareed J, Hoppensteadt DA, Jeske WP, Ahmad S, Bick RL. Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost 1999;25:367-74
6. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993;13:1865-73
7. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 2007;9:218-32
8. Aloia JF, Vaswani A, Russo L, Sheehan M, Flaster E. The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass. Am J Obstet Gynecol 1995;172:896-900
9. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-14
10. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-54
11. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-18
12. Skouby SO, Sidelmann JJ, Nilas L, Jespersen J. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability. Hum Reprod 2007;22:1186-91
13. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95
14. Genazzani AR, Gambacciani M. Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol Endocrinol 2006;22:145-50
15. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B, Bozkaya H. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005;84:384-93
16. Wiegratz I, Starflinger F, Tetzloff W, et al. Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas 2002;41:133-41
17. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997;82:251-3
18. Christodoulakos G, Lambrinoudaki I, Panoulis C, et al. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene. Maturitas 2005;50:321-30
19. Morin-Papunen LC, Vauhkonen I, Ruokonen A, Tapanainen JS, Raudaskoski T. Effects of tibolone and cyclic hormone replacement therapy on glucose metabolism in non-diabetic obese postmenopausal women: a randomized study. Eur J Endocrinol 2004;150:705-14
20. Odmark IS, Carlstrom K, Jonsson B, Jonasson AF. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: effects on carbohydrate metabolism and serum sex hormone-binding globulin. Maturitas 2006;53:89-96
21. Fineberg SE. Glycaemic control and hormone replacement therapy: implications of the Postmenopausal Estrogen/Progestogen Intervention (PEPI) study. Drugs Aging 2000;17:453-61
22. Sites CK. Hormone replacement therapy: cardiovascular benefits for aging women. Coron Artery Dis 1998;9:789-93
23. Manson JE, Rimm EB, Colditz GA et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin- dependent diabetes mellitus. Ann Epidemiol 1992;2:665-73
24. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9
25. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia 2004;47:1175-87
26. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
27. Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23:1889-94
28. Siseles NO, Halperin H, Benencia HJ, et al. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas 1995;21:201-10
29. Le NA, Walter MF. The role of hypertriglyceridemia in atherosclerosis. Curr Atheroscler Rep 2007;9:110-15
30. Yuan G, Al Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007;176:1113-20
31. Madsen JS, Kristensen SR, Gram J, et al. Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women. J Thromb Haemost 2003;1:1984-91
32. Eilertsen AL, Qvigstad E, Andersen TO, Sandvik L, Sandset PM. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. Maturitas 2006;55:278-87
33. Nozaki M, Ogata R, Koera K, Hashimoto K, Nakano H. Changes in coagulation factors and fibrinolytic components of postmenopausal women receiving continuous hormone replacement therapy. Climacteric 1999;2:124-30
34. Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2007;120:371-9
35. Koh KK, Han SH, Shin MS, Ahn JY, Lee Y, Shin EK. Significant differential effects of lower doses of hormone therapy or tibolone on markers of cardiovascular disease in post-menopausal women: a randomized, double-blind, crossover study. Eur Heart J 2005;26:1362-8
36. Norris LA, Joyce M, O'Keeffe N, Sheppard BL, Bonnar J. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002;43:125-33
37. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-19
38. Albert MA. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 2000;2:274-9
39. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006;97:3-11A
40. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8
41. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945-51
42. Garnero P, Jamin C, Benhamou CL, Pelissier C, Roux C. Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial. Hum Reprod 2002;17:2748-53
43. Barnes JF, Farish E, Rankin M, Hart DM. Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. Menopause 2005;12:92-8